NCT04990102View on ClinicalTrials.gov

Phase IB/II of CPX-351 for Relapse Prevention in AML

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

May 22, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Acute Myeloid Leukemia (AML) in Remission
Interventions
DRUG

CPX-351

Daunorubicin 8.8mg/m2 + cytarabine 20mg/m2

Trial Locations (3)

19104

RECRUITING

University of Pennsylvania, Philadelphia

20007

RECRUITING

Georgetown Lombardi Comprehensive Cancer Center, Washington D.C.

07601

RECRUITING

John Theurer Cancer Center at Hackensack University Medical Center, Hackensack

Sponsors

Collaborators (1)

Jazz Pharmaceuticals
All Listed Sponsors
collaborator

Jazz Pharmaceuticals

INDUSTRY

collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Georgetown University

OTHER